SARS‐CoV‐2‐specific humoral and cell‐mediated immune responses after immunization with inactivated COVID‐19 vaccine in kidney transplant recipients (CVIM 1 study)

摘要

Immunogenicity following inactivated SARS‐CoV‐2 vaccination among solid organ transplant recipients has not been assessed. Seventy‐five patients (37 kidney transplant KT recipients and 38 healthy controls) received two doses, at 4‐week intervals, of an inactivated whole‐virus SARS‐CoV‐2 vaccine. SARS‐CoV‐2‐specific humoral (HMI) and cell‐mediated immunity (CMI) were measured before, 4?weeks post‐first dose, and 2?weeks post‐second dose. The median (IQR) age of KT recipients was 50 (42–54) years and 89 were receiving calcineurin inhibitors/mycophenolate/corticosteroid regimens. The median (IQR) time since transplant was 4.5 (2–9.5) years. Among 35 KT patients, the median (IQR) of anti‐RBD IgG level measured by CLIA after vaccination was not different from baseline, but was significantly lower than in controls (2.4 1.1–3.7 vs. 1742.0 747.7–3783.0 AU/ml, p?